Kowalewska Paulina M, Petrik Shawn M, Di Fiore Attilio E, Fox-Robichaud Alison E
Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada (Dr Fox-Robichaud); Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada (Dr Kowalewska); Comparative Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada (Dr Petrik); and ATTWILL Medical Solutions, Inc, West Jordan, Utah (Mr Di Fiore). Paulina M. Kowalewska, PhD, was an Ontario Centres of Excellence TalentEdge Postdoctoral Fellow at McMaster University during this study and is currently a postdoctoral associate at the University of Western Ontario. Shawn M. Petrik, DVM, MSc, Dip LAM, is the leader of the Comparative Medicine Group at McMaster University, which supports veterinarians, physicians, and scientists who study animal models of human diseases. Attilio E. Di Fiore, BSc, BScEng, PEng, is a biomedical engineer specializing in medical device design and development, with extensive experience in vascular device manufacturing and infection control. Alison E. Fox-Robichaud, MD, MSc, FRCPC, is a clinician scientist and professor of medicine with research interests in inflammation and sepsis. She is also a collaborator on various multicenter knowledge translation studies through the Canadian Critical Care Translational Biology Group and the Canadian Critical Care Trials Group.
J Infus Nurs. 2018 Mar/Apr;41(2):103-112. doi: 10.1097/NAN.0000000000000267.
Vascular catheters are a major cause of nosocomial bloodstream infections. ChloraLock (ATTWILL Medical Solutions, Inc, West Jordan, UT, and ICU Medical, Inc, San Clemente, CA) is a novel antimicrobial device containing chlorhexidine digluconate (CHG) that is fitted onto a syringe and infuses CHG into the catheter lumen during locking. The objective of this study was to evaluate the antimicrobial efficacy of ChloraLock with in vitro tests and its ability to reduce Staphylococcus aureus contamination of catheters in the external jugular veins of Yorkshire swine. ChloraLock significantly reduced the bacterial load in the in vitro tests by up to 6 log10 colony-forming units (CFU) and by 3 to 4 log10 CFU/lumen in vivo in a swine model with 0.9% NaCl catheter locks.
血管导管是医院血流感染的主要原因。ChloraLock（ATTWILL医疗解决方案公司，位于犹他州西乔丹市，以及ICU医疗公司，位于加利福尼亚州圣克莱门特市）是一种新型抗菌装置，含有葡萄糖酸氯己定（CHG），安装在注射器上，在封管时将CHG注入导管腔。本研究的目的是通过体外试验评估ChloraLock的抗菌效果及其减少约克郡猪颈外静脉导管金黄色葡萄球菌污染的能力。在体外试验中，ChloraLock显著降低细菌载量，最多可达6个对数10菌落形成单位（CFU），在体内猪模型中，使用0.9%氯化钠封管时，每管腔降低3至4个对数10CFU。
